Table 3 Clinical outcomes of patients on 40 mg of rupatadine and on the placebo.
From: A preliminary study on efficacy of rupatadine for the treatment of acute dengue infection
40 mg rupatadine N = 66 | Placebo N = 67 | P value | |
|---|---|---|---|
Ascites by Ultra sound scan (%) | 15 (22.7) | 18 (26.9) | 0.7 |
Extent of Ascites as measured by US Scan | |||
Mild (%) | 5 (7.6) | 8 (11.9) | 0.56 |
Moderate (%) | 10 (15.1) | 10 (14.9) | 0.7 |
Pleural effusion by Ultra Sound Scan (%) | 7 (10.6) | 5 (7.4) | 0.8 |
Maximum height of pleural effusion | |||
Mean (SD±) | 1.7 (0.4) | 2.85 (1.3) | 0.1 |
Haematocrit >20% rise from baseline | 9 (13.6) | 10 (14.9) | 1.0 |
Acute liver failure (%) | 0 (0) | 2 (3.0) | 0.24 |
Peak ALT levels (median, IQR) | 102.3 (69.2 to 150) | 106.9 (69 to 164.5) | 0.7 |
Peak AST levels (median, IQR) | 115.1 (76.8 to 181.5) | 148 (88.2 to 213.5) | 0.15 |
Duration of illness (days) | |||
Median (IQR) | 7 (6 to 8) | 8 (6 to 9) | 0.09 |
Mean (SD±) | 7.0 (1.4) | 7.5 (1.5) | |
Day of entering the critical phase (15 patients for rupatadine and 18 for placebo) | |||
Median (IQR) | 5 (5 to 5) | 4.5 (4 to 5) | p = 0.03 |
Mean (SD±) | 4.9 (0.9) | 4.5 (0.8) | |
Given normal saline boluses (%) | 0 (0) | 2 (2.98) | 0.24 |
Given dextran (%) | 6 (9.1) | 6 (8.9) | 1.0 |
Given blood (%) | 0 (0) | 1 (1.5) | 0.5 |
Exceeded the fluid quota (%) | 16 (24.2) | 17 (25.4) | 0.8 |
Quantity of extra fluid given Median (IQR) | 362.5 (281.2 to 836.3) | 575 (325 to 1000) | 0.4 |
Platelet nadir during illness (median, IQR) | 53.5 (29.7 to 85.5) | 47 (24 to 83) | 0.5 |
Bleeding (%) | 2 (3.0) | 6 (8.9) | 0.3 |
Vaginal bleeding (% of females) | 2 (15.4) | 4 (25) | |
Epistaxis | 0 (0) | 1 (1.5) | |
GI bleeding | 0 (0) | 1(1.5) | |
